Please select the option that best describes you:
Would you consider the use of pembrolizumab + lenvatinib after progression on first-line carboplatin + paclitaxel + immunotherapy for metastatic endometrial cancer?
Answer from: at Community Practice
Yes, I think this is borderline standard of care now. Adding Lenvima to IO when the cancer recurs seems to usually at least obtain stable disease for a few more months, or even regression.
Sign In or Register to read more